# EDGAR Filing Document

**Accession Number:** 0000059478
**File Stem:** 0000059478-26-000008
**Filing Date:** 2026-2
**Character Count:** 38167
**Document Hash:** 870c5e58567c7367c413dc502df74362
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0000059478-26-000008.hdr.sgml**: 20260204

**ACCESSION NUMBER**: 0000059478-26-000008

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 15

**CONFORMED PERIOD OF REPORT**: 20260204

**ITEM INFORMATION**: Results of Operations and Financial Condition

**ITEM INFORMATION**: Financial Statements and Exhibits

**FILED AS OF DATE**: 20260204

**DATE AS OF CHANGE**: 20260204

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** ELI LILLY & Co
- **CENTRAL INDEX KEY:** 0000059478
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 350470950
- **STATE OF INCORPORATION:** IN
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-06351
- **FILM NUMBER:** 26596007

**BUSINESS ADDRESS:**
- **STREET 1:** LILLY CORPORATE CTR
- **STREET 2:** DROP CODE 1094
- **CITY:** INDIANAPOLIS
- **STATE:** IN
- **ZIP:** 46285
- **BUSINESS PHONE:** 3172762000

**MAIL ADDRESS:**
- **STREET 1:** LILLY CORPORATE CENTER
- **STREET 2:** DROP CODE 1094
- **CITY:** INDIANAPOLIS
- **STATE:** IN
- **ZIP:** 46285

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** LILLY ELI & CO
- **DATE OF NAME CHANGE:** 19941024

?xml version='1.0' encoding='ASCII'? lly-20260204

**UNITED STATES**<br>**SECURITIES AND EXCHANGE COMMISSION**<br>**Washington, D.C. 20549**<br>

 

**FORM 8-K** 

 

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d)**

**of the Securities Exchange Act of 1934**

**Date of Report (Date of Earliest Event Reported): February 4, 2026**

 

**ELI LILLY AND COMPANY** 

 **(Exact Name of Registrant as Specified in its Charter)** 

 

---

| | | |
|:---|:---|:---|
| **Indiana** | **001-06351** | **35-0470950** |
| **(State or Other Jurisdiction<br>of Incorporation)** | **(Commission<br>File Number)** | **(I.R.S. Employer<br>Identification No.)** |

---

---

| | | |
|:---|:---|:---|
| **Lilly Corporate Center** | **Lilly Corporate Center** | |
| **Indianapolis,** | **Indiana** | **46285** |
| **(Address of Principal Executive Offices)** | **(Address of Principal Executive Offices)** | **(Zip Code)** |

---

**Registrant's Telephone Number, Including Area Code: (317) 276-2000** 

**Not Applicable**

 **(Former Name or Former Address, if Changed Since Last Report.)** 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (<u>see</u> General Instruction A.2.):

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

------

Securities registered pursuant to Section 12(b) of the Act:

---

| | | |
|:---|:---|:---|
| **Title of each class** | **Trading Symbol(s)** | **Name of each exchange on which registered** |
| Common Stock (no par value) | LLY | New York Stock Exchange |
| 1.625% Notes due 2026 | LLY26 | New York Stock Exchange |
| 2.125% Notes due 2030 | LLY30 | New York Stock Exchange |
| 0.625% Notes due 2031 | LLY31 | New York Stock Exchange |
| 0.500% Notes due 2033 | LLY33 | New York Stock Exchange |
| 6.77% Notes due 2036 | LLY36 | New York Stock Exchange |
| 1.625% Notes due 2043 | LLY43 | New York Stock Exchange |
| 1.700% Notes due 2049 | LLY49A | New York Stock Exchange |
| 1.125% Notes due 2051 | LLY51 | New York Stock Exchange |
| 1.375% Notes due 2061 | LLY61 | New York Stock Exchange |

---

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

------

**Item 2.02. Results of Operations and Financial Condition.**

The information in this Item 2.02, including Exhibit 99.1 attached hereto, is being furnished and shall not be deemed "filed" for the purposes of Section 18 of the Securities Exchange Act of 1934 (the "Exchange Act"), or otherwise subject to the liabilities of that Section and shall not be incorporated by reference into any registration statement or other document filed pursuant to the Securities Act of 1933 or the Exchange Act, except as otherwise expressly stated in such filing.

Attached hereto as Exhibit 99.1 and incorporated by reference into this Item 2.02 is a copy of the press release, dated February 4, 2026, announcing the financial results of Eli Lilly and Company for the quarter and year ended December 31, 2025.

------

**Item 9.01. Financial Statements and Exhibits.**

---

| | |
|:---|:---|
| **<u>Exhibit No.</u>** | **<u>Description</u>** |
| <u>[99.1](q425lillysalesandearningsp.htm)</u> | <u>[Press Release of Eli Lilly and Company, dated](q425lillysalesandearningsp.htm)[February 4](q425lillysalesandearningsp.htm)[, 202](q425lillysalesandearningsp.htm)[6](q425lillysalesandearningsp.htm)[.](q425lillysalesandearningsp.htm)</u> |
| 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document). |

---

------

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

---

| | |
|:---|:---|
| **ELI LILLY AND COMPANY** | **ELI LILLY AND COMPANY** |
| (Registrant) | (Registrant) |
| By: | /s/ Donald A. Zakrowski |
| Name: | Donald A. Zakrowski |
| Title: | Senior Vice President, Finance, and <br>Chief Accounting Officer |
| Date: | February 4, 2026 |

---

## Exhibit 99.1

![logoa31.jpg](logoa31.jpg)

February 4, 2026

**For release:&nbsp;&nbsp;&nbsp;&nbsp;**Immediately

**Refer to:&nbsp;&nbsp;&nbsp;&nbsp;**Ashley Hennessey; gentry_ashley_jo@lilly.com; (317) 416-4363 (Media)

Mike Czapar; czapar_michael_c@lilly.com; (317) 617-0983 (Investors)

**Lilly reports fourth-quarter 2025 financial results and provides 2026 guidance** 

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;*• Revenue in Q4 2025 increased 43% to $19.3 billion driven by volume growth from Mounjaro and Zepbound*.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;*• Q4 2025 EPS increased by 51% to $7.39 on a reported basis and increased by 42% to $7.54 on a non-GAAP basis, both inclusive of $0.52 of acquired IPR&D charges.*

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;*• Regulatory progress included FDA approval of Kwikpen for tirzepatide and an expanded indication for Jaypirca, and submissions for orforglipron for obesity to regulatory authorities in the U.S. and Japan and for obesity and type 2 diabetes in the EU.* 

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;*• Pipeline progress included positive Phase 3 results from Taltz and Zepbound used together for adults with active psoriatic arthritis and obesity, orforglipron for people who switched from injectable incretins to oral GLP-1 therapy, and retatrutide for people with obesity and knee osteoarthritis.*

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;*• Announced an agreement with the U.S. government to expand access to obesity medicines for millions of Americans.*

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;*• 2026 guidance issued with revenue in the range of $80 billion to $83 billion and non-GAAP EPS in the range of $33.50 to $35.00.* 

INDIANAPOLIS, February 4, 2026 - Eli Lilly and Company (NYSE: LLY) today announced its financial results for the fourth-quarter of 2025 and provided 2026 financial guidance.

"2025 was an important year for Lilly," said David A. Ricks, Lilly's chair and CEO. "We reached millions more patients—launching Inluriyo, expanding Mounjaro and Kisunla globally, and submitting orforglipron for approval. We expanded our manufacturing capacity, and through our U.S. government agreement, opened new access to obesity medicines. Entering our 150th year with a deep pipeline and platforms like LillyDirect, we're positioned to reach more patients than ever and expand our global health impact."

**Eli Lilly and Company** \| Lilly Corporate Center \| Indianapolis, Indiana 46285 \| U.S.A.

------

<u>Financial Results</u>

---

| | | | |
|:---|:---|:---|:---|
| $ in millions, except <br>per share data | <u>Fourth-Quarter</u> | <u>Fourth-Quarter</u> | <u>Fourth-Quarter</u> |
|  | <u>2025</u> | <u>2024</u> | <u>% Change</u> |
| Revenue | $19292 | $13533 | 43% |
| Net income – Reported | 6636 | 4410 | 50% |
| Earnings per share – Reported | 7.39 | 4.88 | 51% |
| Net income – Non-GAAP | 6771 | 4806 | 41% |
| Earnings per share – Non-GAAP | 7.54 | 5.32 | 42% |

---

A discussion of the non-GAAP financial measures is included below under "Reconciliation of GAAP Reported to Selected Non-GAAP Adjusted Information (Unaudited)."

<u>Fourth-Quarter Reported Results</u>

In Q4 2025, worldwide revenue was $19.3 billion, an increase of 43% compared with Q4 2024, driven by a 46% increase in volume, partially offset by a 5% decrease due to lower realized prices. Key Products<sup>1</sup> revenue grew to $13.8 billion in Q4 2025, led by Mounjaro and Zepbound.

Revenue in the U.S. increased 43% to $12.9 billion, driven by a 50% increase in volume, partially offset by a 7% decrease due to lower realized prices. The increase in U.S. volume and decline in realized prices were driven by Zepbound and Mounjaro.

Revenue outside the U.S. increased 43% to $6.4 billion, driven by a 38% increase in volume and to a lesser extent a 4% favorable impact on foreign exchange rates. The volume increase outside the U.S. was driven primarily by Mounjaro, partially offset by Jardiance. Volume growth was negatively impacted by a one-time benefit of $300 million related to Jardiance, associated with an amendment to the company's collaboration with Boehringer Ingelheim, in Q4 2024.

Gross margin increased 43% to $15.9 billion in Q4 2025. Gross margin as a percent of revenue was 82.5%, an increase of 0.3 percentage points. The increase in gross margin percent was primarily driven by favorable product mix and improved cost of production, partially offset by lower realized prices.

<sup>1</sup> The Company defines Key Products as Ebglyss, Inluriyo (effective Q4 2025), Jaypirca, Kisunla, Mounjaro, Omvoh, Verzenio and Zepbound.

2

------

In Q4 2025, research and development expenses increased 26% to $3.8 billion, or 20% of revenue, driven by continued investments in the company's early and late-stage portfolio.

Marketing, selling and administrative expenses increased 29% to $3.1 billion in Q4 2025, primarily driven by promotional efforts supporting ongoing and planned launches.

The effective tax rate was 19.7% in Q4 2025 compared with 12.5% in Q4 2024 primarily driven by a less favorable jurisdictional mix of earnings in Q4 2025 relative to Q4 2024. Additionally, the effective tax rate for Q4 2025 was unfavorably impacted by U.S. tax law changes enacted earlier in 2025.

In Q4 2025, net income and earnings per share (EPS) were $6.6 billion and $7.39, respectively, compared with net income of $4.4 billion and EPS of $4.88 in Q4 2024. EPS in Q4 2025 and Q4 2024 included acquired IPR&D charges of $0.52 and $0.19, respectively.

<u>Fourth-Quarter Non-GAAP Measures</u>

On a non-GAAP basis, Q4 2025 gross margin increased 42% to $16.0 billion. Gross margin as a percent of revenue was 83.2%, consistent with Q4 2024. Favorable product mix and improved cost of production were offset by lower realized prices.

The non-GAAP effective tax rate was 19.7% in Q4 2025 compared with 13.2% in Q4 2024 primarily driven by a less favorable jurisdictional mix of earnings in Q4 2025 relative to Q4 2024. Additionally, the effective tax rate for Q4 2025 was unfavorably impacted by U.S. tax law changes enacted earlier in 2025.

On a non-GAAP basis, Q4 2025 net income and EPS were $6.8 billion and $7.54, respectively, compared with net income of $4.8 billion and EPS of $5.32 in Q4 2024. Non-GAAP EPS in Q4 2025 and Q4 2024 included acquired IPR&D charges of $0.52 and $0.19, respectively.

3

------

For further detail on non-GAAP measures, see the reconciliation below as well as the "Reconciliation of GAAP Reported to Selected Non-GAAP Adjusted Information (Unaudited)" table later in this press release.

---

| | | | |
|:---|:---|:---|:---|
| | <u>Fourth-Quarter</u> | <u>Fourth-Quarter</u> | <u>Fourth-Quarter</u> |
| | <u>2025</u> | <u>2024</u> | <u>% Change</u> |
| **Earnings per share (reported)** | $**7.39** | $**4.88** | **51%** |
| Amortization of intangible assets | .11 | .12 |  |
| Asset impairment, restructuring and other special charges | .07 | .30 |  |
| Net losses (gains) on investments in equity securities | (.03) | .02 |  |
| **Earnings per share (non-GAAP)** | $**7.54** | $**5.32** | **42%** |
| Acquired IPR&D | .52 | .19 | 174% |
| Numbers may not add due to rounding |  |  |  |

---

4

------

Selected Revenue Highlights

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
| *(Dollars in millions)* | <u>Fourth-Quarter</u> | <u>Fourth-Quarter</u> | <u>Fourth-Quarter</u> | <u>Full Year</u> | <u>Full Year</u> | <u>Full Year</u> |
| **Selected Products** | <u>2025</u> | <u>2024</u> | <u>% Change</u> | <u>2025</u> | <u>2024</u> | <u>% Change</u> |
| &nbsp;&nbsp;&nbsp;&nbsp;Mounjaro | $7409 | $3530 | 110% | $22965 | $11540 | 99% |
| &nbsp;&nbsp;&nbsp;&nbsp;Zepbound<sup>(1)</sup> | 4261 | 1907 | 123% | 13542 | 4926 | 175% |
| &nbsp;&nbsp;&nbsp;&nbsp;Verzenio | 1604 | 1555 | 3% | 5723 | 5307 | 8% |
| **Total Revenue** | 19292 | 13533 | 43% | 65179 | 45043 | 45% |
| <sup>(1)</sup> Tirzepatide is marketed for obesity under the brand name Zepbound in Canada, Japan, and the United States. | <sup>(1)</sup> Tirzepatide is marketed for obesity under the brand name Zepbound in Canada, Japan, and the United States. | <sup>(1)</sup> Tirzepatide is marketed for obesity under the brand name Zepbound in Canada, Japan, and the United States. | <sup>(1)</sup> Tirzepatide is marketed for obesity under the brand name Zepbound in Canada, Japan, and the United States. | <sup>(1)</sup> Tirzepatide is marketed for obesity under the brand name Zepbound in Canada, Japan, and the United States. | <sup>(1)</sup> Tirzepatide is marketed for obesity under the brand name Zepbound in Canada, Japan, and the United States. | <sup>(1)</sup> Tirzepatide is marketed for obesity under the brand name Zepbound in Canada, Japan, and the United States. |

---

<u>Mounjaro</u>

For Q4 2025, worldwide Mounjaro revenue increased 110% to $7.4 billion. U.S. revenue was $4.1 billion, an increase of 57%, reflecting strong demand, partially offset by lower realized prices. Revenue outside the U.S. increased to $3.3 billion compared with $899 million in Q4 2024, primarily driven by volume growth.

<u>Zepbound</u>

For Q4 2025, U.S. Zepbound revenue increased 122% to $4.2 billion, compared with $1.9 billion in Q4 2024, primarily driven by increased demand, partially offset by lower realized prices.

<u>Verzenio</u>

For Q4 2025, worldwide Verzenio revenue increased 3% to $1.6 billion. U.S. revenue was $997 million, a decrease of 4%. Revenue outside the U.S. was $608 million, an increase of 18%, primarily driven by volume growth.

5

------

Lilly shared numerous updates recently on key regulatory, clinical, business development and other events, including:

---

| | | |
|:---|:---|:---|
| **Regulatory** | Lilly's sofetabart mipitecan receives U.S. FDA's Breakthrough Therapy designation for the treatment of certain patients with platinum-resistant ovarian cancer (announcement) |  |
| **Regulatory** | U.S. FDA approves expanded indication for Lilly's Jaypirca (pirtobrutinib), the first and only non-covalent (reversible) BTK inhibitor, for adults with relapsed or refractory CLL/SLL previously treated with a covalent BTK inhibitor (announcement) |  |
| **Clinical** | Lilly's Taltz (ixekizumab) and Zepbound (tirzepatide) used together delivered superior efficacy in first-of-its-kind Phase 3b trial for adults with active psoriatic arthritis and obesity or overweight (announcement) |  |
| **Clinical** | Lilly's orforglipron helped people maintain weight loss after switching from injectable incretins to oral GLP-1 therapy in first-of-its-kind Phase 3 trial (announcement) |  |
| **Clinical** | Updated data for Lilly's Inluriyo™ (imlunestrant) reinforce efficacy results as monotherapy and in combination with Verzenio® (abemaciclib) in ER+, HER2- advanced breast cancer (announcement) |  |
| **Clinical** | Lilly's triple agonist, retatrutide, delivered weight loss of up to an average of 71.2 lbs along with substantial relief from osteoarthritis pain in first successful Phase 3 trial (announcement) |  |
| **Clinical** | Lilly's Jaypirca (pirtobrutinib) significantly improved progression-free survival, reducing the risk of progression or death by 80%, versus chemoimmunotherapy in patients with treatment-naïve CLL/SLL (announcement) |  |
| **Clinical** | Lilly's Jaypirca (pirtobrutinib) met its primary endpoint in first-of-its-kind, head-to-head Phase 3 study versus Imbruvica (ibrutinib) (announcement) |  |
| **Clinical** | Lilly's selective amylin agonist, eloralintide, demonstrated meaningful weight loss and favorable tolerability in a Phase 2 study of adults with obesity or overweight (announcement) |  |
| **Clinical** | **Other** | Lilly selects Pennsylvania as home for its newest injectable medicine and device manufacturing facility (announcement) |
| NVIDIA and Lilly Announce Co-Innovation AI Lab to Reinvent Drug Discovery In the Age of AI (announcement) | **Other** |  |
| Lilly to acquire Ventyx Biosciences to advance oral therapies targeting inflammatory-mediated diseases (announcement) | **Other** |  |
| Lilly to build $6 billion facility to manufacture active pharmaceutical ingredients in Alabama (announcement) | **Other** |  |
| Lilly and Adverum announce expiration and completion of Adverum tender offer and acquisition (announcement) | **Other** |  |
| Carolyn Bertozzi returns to Lilly board of directors (announcement) | **Other** |  |
| Lilly announces plans to open Lilly Gateway Labs site in Philadelphia (announcement) | **Other** |  |
| Lilly announces two new Executive Committee members and expansion of leadership roles to prepare for next wave of growth (announcement) | **Other** |  |
| Lilly and U.S. government agree to expand access to obesity medicines to millions of Americans (announcement) | **Other** |  |
| Lilly plans to build a new $3 billion facility to boost oral medicine manufacturing capacity in Europe for patients worldwide (announcement) | **Other** |  |
| **Other** |  |  |

---

For information on important public announcements, visit the news section of Lilly's website.

6

------

<u>2026 Financial Guidance</u> 

In addition to providing guidance for GAAP revenue, Lilly provides guidance for certain non-GAAP measures. Lilly does not provide reconciliations of forward-looking non-GAAP measures to the most directly comparable GAAP measures because comparable GAAP measures are not reasonably accessible or reliable due to the inherent difficulty in forecasting and quantifying measures that would be necessary for a reconciliation. In particular, Lilly cannot reasonably predict certain items including net gains and losses on equity securities, asset impairment, acquisition or divestiture-related items, restructuring and other adjustments, without unreasonable effort. These items are uncertain, depend on various factors, and could have a material impact on Lilly's reported results in accordance with GAAP.

The following table summarizes the company's full-year 2026 financial guidance:

---

| | |
|:---|:---|
| | **2026 Guidance** |
| Revenue | $80 to $83 billion |
| Performance Margin<sup>(1)(2)</sup> | 46.0% to 47.5% |
| Tax Rate<sup>(2)(3)</sup> | 18% to 19% |
| Earnings per Share<sup>(2)(3)(4)</sup> | $33.50 to $35.00 |
| <sup>(1)</sup> The Company defines performance margin as gross margin less research and development and marketing, selling, and administrative expenses divided by revenue. | <sup>(1)</sup> The Company defines performance margin as gross margin less research and development and marketing, selling, and administrative expenses divided by revenue. |
| <sup>(2)</sup> Excludes the impact of intangible asset amortization. | <sup>(2)</sup> Excludes the impact of intangible asset amortization. |
| <sup>(3)</sup> Guidance does not include acquired in-process research and development (IPR&D) either incurred or expected to be incurred, after December 31, 2025.  | <sup>(3)</sup> Guidance does not include acquired in-process research and development (IPR&D) either incurred or expected to be incurred, after December 31, 2025.  |
| <sup>(4)</sup> 2026 assumes shares outstanding of approximately 894 million | <sup>(4)</sup> 2026 assumes shares outstanding of approximately 894 million |

---

7

------

**Webcast of Conference Call**

As previously announced, investors and the general public can access a live webcast of the Q4 2025 financial results conference call through a link on Lilly's website at investor.lilly.com/webcasts-and-presentations. The conference call will begin at 10 a.m. Eastern time today and will be available for replay via the website.

**Non-GAAP Financial Measures**

Certain financial information is presented on both a reported and a non-GAAP basis. Some numbers in this press release may not add due to rounding. Reported results were prepared in accordance with U.S. generally accepted accounting principles (GAAP) and include all revenue and expenses recognized during the periods. Historical non-GAAP measures reflect adjustments for the items described in the reconciliation tables later in the release. Related materials provide certain GAAP and non-GAAP figures excluding the impact of foreign exchange rates. Lilly recalculates current period figures on a constant currency basis by keeping constant the exchange rates from the base period. The company's 2026 financial guidance (other than revenue) is provided on a non-GAAP basis, as described in "2026 Financial Guidance" above. Non-GAAP measures are presented to provide additional insights into the underlying trends in the company's business.

**About Lilly**

Lilly is a medicine company turning science into healing to make life better for people around the world. We've been pioneering life-changing discoveries for nearly 150 years, and today our medicines help tens of millions of people across the globe. Harnessing the power of biotechnology, chemistry and genetic medicine, our scientists are urgently advancing new discoveries to solve some of the world's most significant health challenges: redefining diabetes care; treating obesity and curtailing its most devastating long-term effects; advancing the fight against Alzheimer's disease; providing solutions to some of the most debilitating immune system disorders; and transforming the most difficult-to-treat cancers into manageable diseases. With each step toward a healthier world, we're motivated by one thing: making life better for millions more people. That includes delivering innovative clinical trials that reflect the diversity of our world and working to ensure our medicines are accessible and affordable. To learn more, visit Lilly.com and Lilly.com/news. F-LLY

8

------

**Cautionary Statement Regarding Forward-Looking Statements**

This press release and the related attachments contain management's intentions and expectations for the future, all of which are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. The words "estimate", "project", "intend", "expect", "believe", "target", "plan", "anticipate", "may", "could", "aim", "seek", "will", "continue", and similar expressions are intended to identify forward-looking statements. Actual results may differ materially due to various factors. The following include some but not all of the factors that could cause actual results or events to differ from those anticipated, including the significant costs and uncertainties in the pharmaceutical research and development process, including with respect to the timing and process of obtaining regulatory approvals and the ability of the company's clinical trials to meet expectations; the impact and uncertain outcome of acquisitions and business development transactions and related costs; intense competition affecting the company's products, pipeline, or industry; market uptake of launched products and indications; continued pricing pressures and the impact of actions of governmental and private actors affecting pricing of, reimbursement for, and patient access to pharmaceuticals, or reporting obligations related thereto; the negotiation and implementation of our voluntary agreement with the U.S. government related to drug pricing and access; Developments or uncertainties related to our or competitive products, including as may relate to safety or efficacy concerns; dependence on relatively few products or product classes for a significant percentage of the company's total revenue and a consolidated supply chain; the expiration of intellectual property protection for certain of the company's products and competition from generic and biosimilar products; the company's ability to protect and enforce patents and other intellectual property and changes in patent law or regulations related to data package exclusivity; information technology system inadequacies, inadequate controls or procedures, security breaches, or operating failures; unauthorized access, disclosure, misappropriation, or compromise of confidential information or other data stored in the company's information technology systems, networks, and facilities, or those of third parties with whom the company shares its data and violations of data protection laws or regulations; issues with product supply, regulatory approvals, or other negative outcomes stemming from manufacturing difficulties, disruptions, or shortages, including as a result of unpredictability and variability in demand, labor shortages, third-party performance, quality, cyber-attacks, or regulatory actions related to the company's and third-party facilities; reliance on third-party relationships and outsourcing arrangements; the use of artificial intelligence or other emerging technologies in various facets of the company's operations, including partnerships related to the use of, or the sharing of such technologies with third parties, which may exacerbate competitive, regulatory, litigation, cybersecurity, and other risks; the impact of global macroeconomic conditions, including uneven economic growth or downturns or uncertainty, trade and other global disputes and interruptions, including related to tariffs, trade protection measures, and similar restrictions, international tension, conflicts, regional dependencies, or other costs, uncertainties, and risks related to engaging in business globally; fluctuations in foreign currency exchange rates, changes in interest rates and inflation or deflation; significant and sudden declines or volatility in the trading price of the company's common stock and market capitalization; litigation, investigations, or other similar proceedings involving past, current, or future products, activities, or intellectual property; changes in tax law and regulations, tax rates, or events that differ from our assumptions related to tax positions; regulatory changes, developments, and uncertainty; regulatory oversight and actions regarding the company's operations and products; regulatory compliance problems or government investigations; risks from the proliferation of counterfeit, misbranded, adulterated, diverted or illegally compounded products; actual or perceived deviation from environmental-, social-, or governance-related requirements or expectations; asset impairments and restructuring charges; and changes in accounting and reporting standards. For additional information about the factors that could cause actual results or events to differ materially from forward-looking statements, please see the company's latest Form 10-K and subsequent Forms 8-K and 10-Q filed with the Securities and Exchange Commission. You should not place undue reliance on forward-looking statements contained in this press release and the related attachments, which, except as otherwise noted, speak only as of the date of this release. Except as is required by law, the company expressly disclaims any obligation to publicly release any revisions to forward-looking statements contained in this press release and the related attachments to reflect events or circumstances after the date of this release.

&nbsp;&nbsp;&nbsp;&nbsp;#&nbsp;&nbsp;&nbsp;&nbsp;#&nbsp;&nbsp;&nbsp;&nbsp;#

**Website Information**

The information contained on, or that may be accessed through, our website or any third-party website is not incorporated by reference into, and is not a part of, this earnings release.

**Trademarks and Trade Names**

All trademarks or trade names referred to in this press release are the property of the company, or, to the extent trademarks or trade names belonging to other companies are referenced in this press release, the property of their respective owners. Solely for convenience, the trademarks and trade names in this press release are referred to without the® and™ symbols, but such references should not be construed as any indicator that the company or, to the extent applicable, their respective owners will not assert, to the fullest extent under applicable law, the company's or their rights thereto. We do not intend the use or display of other companies' trademarks and trade names to imply a relationship with, or endorsement or sponsorship of us by, any other companies.

9

------

---

| |
|:---|
| Eli Lilly and Company |
| Operating Results (Unaudited) – REPORTED |
| (Dollars in millions, except per share data; numbers may not add due to rounding) |

---

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
| | Three Months Ended | Three Months Ended | Three Months Ended | Twelve Months Ended | Twelve Months Ended | Twelve Months Ended |
| | December 31, | December 31, | December 31, | December 31, | December 31, | December 31, |
| | 2025 | 2024 | % Chg. | 2025 | 2024 | % Chg. |
| Revenue | $19292 | $13533 | 43% | $65179 | $45043 | 45% |
| Cost of sales | 3372 | 2404 | 40% | 11052 | 8418 | 31% |
| Research and development | 3802 | 3023 | 26% | 13337 | 10991 | 21% |
| Marketing, selling and administrative | 3132 | 2424 | 29% | 11094 | 8594 | 29% |
| Acquired IPR&D | 529 | 189 | 180% | 2910 | 3280 | (11)% |
| Asset impairment, restructuring and other special charges | 84 | 344 | (76)% | 484 | 861 | (44)% |
| &nbsp;&nbsp;&nbsp;&nbsp;Operating income | 8373 | 5149 | 63% | 26302 | 12899 | 104% |
| &nbsp;&nbsp;&nbsp;&nbsp;Net interest income (expense) | (123) | (181) |  | (642) | (606) |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Net other income (expense) | 15 | 71 |  | 71 | 387 |  |
| Other income (expense) | (108) | (110) | (2)% | (571) | (219) | 161% |
| Income before income taxes | 8265 | 5039 | 64% | 25731 | 12680 | 103% |
| Income tax expense | 1629 | 629 | 159% | 5091 | 2090 | 144% |
| Net income | $6636 | $4410 | 50% | $20640 | $10590 | 95% |
| Earnings per share - diluted | $7.39 | $4.88 | 51% | $22.95 | $11.71 | 96% |
| Dividends paid per share | $1.50 | $1.30 | 15% | $6.00 | $5.20 | 15% |
| Weighted-average shares outstanding (thousand) - diluted | 898002 | 903158 |  | 899301 | 904059 |  |

---

10

------

---

| | | | | |
|:---|:---|:---|:---|:---|
| Eli Lilly and Company | Eli Lilly and Company | Eli Lilly and Company | Eli Lilly and Company | Eli Lilly and Company |
| Reconciliation of GAAP Reported to Selected Non-GAAP Adjusted Information (Unaudited) | Reconciliation of GAAP Reported to Selected Non-GAAP Adjusted Information (Unaudited) | Reconciliation of GAAP Reported to Selected Non-GAAP Adjusted Information (Unaudited) | Reconciliation of GAAP Reported to Selected Non-GAAP Adjusted Information (Unaudited) | Reconciliation of GAAP Reported to Selected Non-GAAP Adjusted Information (Unaudited) |
| (Dollars in millions, except per share data; numbers may not add due to rounding) | (Dollars in millions, except per share data; numbers may not add due to rounding) | (Dollars in millions, except per share data; numbers may not add due to rounding) | (Dollars in millions, except per share data; numbers may not add due to rounding) | (Dollars in millions, except per share data; numbers may not add due to rounding) |
|  | Three Months Ended December 31, | Three Months Ended December 31, | Twelve Months Ended,<br>December 31, | Twelve Months Ended,<br>December 31, |
|  | 2025 | 2024 | 2025 | 2024 |
| **Gross Margin - As Reported** | $**15920** | $**11129** | $**54127** | $**36625** |
| Increase for excluded items: |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Amortization of intangible assets (Cost of sales)<sup>(1)</sup> | 124 | 136 | 488 | 553 |
| Gross Margin - Non-GAAP | $16044 | $11265 | $54615 | $37178 |
| **Gross Margin as a percent of revenue - As Reported** | **82.5%** | **82.2%** | **83.0%** | **81.3%** |
| Gross Margin as a percent of revenue - Non-GAAP<sup>(2)</sup> | 83.2% | 83.2% | 83.8% | 82.5% |

---

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1.Excludes amortization of intangibles primarily associated with costs of marketed products acquired or licensed from third parties.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2. Non-GAAP gross margin as a percent of revenue reflects the gross margin effects of the adjustments presented above.

11

------

---

| | | | | |
|:---|:---|:---|:---|:---|
| Reconciliation of GAAP Reported to Selected Non-GAAP Adjusted Information (Unaudited) | Reconciliation of GAAP Reported to Selected Non-GAAP Adjusted Information (Unaudited) | Reconciliation of GAAP Reported to Selected Non-GAAP Adjusted Information (Unaudited) | Reconciliation of GAAP Reported to Selected Non-GAAP Adjusted Information (Unaudited) | Reconciliation of GAAP Reported to Selected Non-GAAP Adjusted Information (Unaudited) |
| (Dollars in millions, except per share data; numbers may not add due to rounding) | (Dollars in millions, except per share data; numbers may not add due to rounding) | (Dollars in millions, except per share data; numbers may not add due to rounding) | (Dollars in millions, except per share data; numbers may not add due to rounding) | (Dollars in millions, except per share data; numbers may not add due to rounding) |
|  | Three Months Ended December 31, | Three Months Ended December 31, | Twelve Months Ended,<br>December 31, | Twelve Months Ended,<br>December 31, |
|  | 2025 | 2024 | 2025 | 2024 |
| **Net income - Reported** | $**6636** | $**4410** | $**20640** | $**10590** |
| Increase (decrease) for excluded items: |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Amortization of intangible assets (Cost of sales)<sup>(1)</sup> | 124 | 136 | 488 | 553 |
| &nbsp;&nbsp;&nbsp;&nbsp;Asset impairment, restructuring and other special charges<sup>(2)</sup> | 84 | 344 | 484 | 861 |
| &nbsp;&nbsp;&nbsp;&nbsp;Net (gains) losses on investments in equity securities (Other income/expense) | (39) | 17 | (33) | 39 |
| &nbsp;&nbsp;&nbsp;&nbsp;U.S. Tax Law Change<sup>(3)</sup> |  |  | 350 |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Corresponding tax effects (Income taxes) | (34) | (101) | (161) | (296) |
| Net income - Non-GAAP | $6771 | $4806 | $21768 | $11747 |
| **Effective tax rate - Reported** | **19.7%** | **12.5%** | **19.8%** | **16.5%** |
| Effective tax rate - Non-GAAP<sup>(4)</sup> | 19.7% | 13.2% | 18.4% | 16.9% |
| **Earnings per share (diluted) - Reported** | $**7.39** | $**4.88** | $**22.95** | $**11.71** |
| Earnings per share (diluted) - Non-GAAP | $7.54 | $5.32 | $24.21 | $12.99 |

---

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1.Excludes amortization of intangibles primarily associated with costs of marketed products acquired or licensed from third parties.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2. For the three months ended December 31, 2025, excluded charges primarily related to an intangible asset impairment acquired through POINT BioPharma Global Inc.. For the twelve months ended December 31, 2025, also excluded charges primarily related to litigation, as well as acquisition and integration costs associated with Verve Therapeutics, Inc. For the three months ended December 31, 2024, excluded charges related to intangible asset impairment for Vitrakvi. For the twelve months ended December 31, 2024, also excluded charges related to litigation.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3. Relates to adjusting our income tax provision for prior periods and remeasuring our deferred tax assets and liabilities.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4. Non-GAAP tax rate reflects the tax effects of the adjustments presented above.

12